Vernalis' Frova: Mixed Blessing
Executive SummaryVernalis Group PLC is one of the few European biotechs to register a drug in the EU and the US. But delays in getting migraine treatment frovatriptan to an already crowded market mean the project has cost more than it's likely to recoup in the near term.
You may also be interested in...
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.
Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.